IMAC Holdings Competitors
| BACK Stock | USD 0.06 0.0015 2.67% |
IMAC Holdings and BriaCell Therapeutics Correlation Snapshot
Poor diversification
BACK currently posts a 0.63 correlation with BCTXW, indicating a Poor diversification relationship for the active sample. This matters because lower overlap can improve diversification, while higher overlap leaves more of the same risk inside the portfolio.
Moving against IMAC OTC Stock
The concept of mean reversion suggests that IMAC Holdings' price will eventually return toward its long-run average. High prices may deter value investors, while unusually low prices often attract buyers who anticipate a recovery.
IMAC Holdings Competition Correlation Matrix
Correlation analysis between IMAC Holdings and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. The useful question is whether competitors are behaving like true alternatives or simply tracking the same sector move with different volatility.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Evaluating IMAC OTC Stock requires separating price momentum from underlying business quality relative to competitors. Without reviewing risk-adjusted indicators, investors may overweight recent returns and underweight the volatility required to achieve them. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NLSP | 5.08 | -1.06 | 0.00 | -0.49 | 0.00 | 8.33 | 43.14 | |||
| PRE | 4.20 | 0.78 | 0.16 | 0.45 | 4.16 | 13.33 | 27.11 | |||
| NUWE | 6.30 | -0.51 | 0.00 | -0.42 | 0.00 | 9.09 | 100.50 | |||
| OCEA | 46.59 | 13.90 | 0.35 | -2.51 | 29.89 | 166.67 | 473.33 | |||
| PIII | 6.43 | -0.26 | 0.00 | -0.35 | 0.00 | 22.22 | 48.13 | |||
| CERO | 5.27 | -1.31 | 0.00 | -0.88 | 0.00 | 13.64 | 39.49 | |||
| DRMA | 7.63 | -0.57 | 0.00 | -0.46 | 0.00 | 16.48 | 80.83 | |||
| ACON | 5.28 | -0.35 | 0.00 | -0.24 | 0.00 | 10.64 | 83.58 | |||
| PPBT | 2.84 | -0.90 | 0.00 | -0.97 | 0.00 | 6.77 | 19.93 | |||
| BCTXW | 11.59 | -4.59 | 0.00 | 1.52 | 0.00 | 14.21 | 98.33 |
IMAC Holdings Competitive Analysis
IMAC Holdings' competitive standing becomes clearer when measured alongside NLS Pharmaceutics, Prenetics Global, and Nuwellis. With 5.2 M in revenue and a 185,122 market value, IMAC Holdings anchors one end of the peer spectrum. IMAC Holdings posts a -332.19% return on equity, reflecting current earnings headwinds. Market capitalization diverges sharply here: 4.0 M versus 185,122, giving NLS Pharmaceutics a clear size advantage. Prenetics Global pulls in 92.4 M in revenue while IMAC Holdings reports 5.2 M. Return on equity favors IMAC Holdings at -332.19%, well ahead of Nuwellis at -467.14%.| Better Than Average | Worse Than Peers | View Performance Chart |
IMAC Holdings Competition Peer Performance Charts
How to Analyze IMAC Holdings Against Peers
IMAC Holdings' peer analysis compares IMAC Holdings with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether IMAC Holdings trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where IMAC Holdings leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Return on invested capital comparison for IMAC Holdings versus peers reveals which companies in the group are genuinely creating value versus just growing the top line. Peer benchmarking can improve context for valuation without relying only on standalone multiples. For peer comparison, IMAC Holdings has a market cap of 185.12 K.
For IMAC Holdings, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist.